Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 3:11 AM
Ignite Modification Date:
2025-12-26 @ 1:49 AM
NCT ID:
NCT01355705
Group ID:
EG000
Title:
Amrubicin + Lenalidomide + Dexamethasone
Description:
Amrubicin 40, 60, or 80 mg/m2 intravenous (IV) will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.
Concurrent therapeutic medications:
* Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14
* Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)
Other drugs:
* Aspirin: 81 or 325 mg daily oral
* Pegfilgrastim subcutaneous on Day 2
Deaths Number Affected:
None
Deaths Number At Risk:
None
Serious Number Affected:
3
Serious Number At Risk:
14
Other Number Affected:
12
Other Number At Risk:
14
Study:
NCT01355705
Results Section:
NCT01355705
Adverse Events Module:
NCT01355705